Data Analytics as a Catalyst for Medical Innovation

Transcription

1 Data Analytics as a Catalyst for Medical Innovation A Patient Journey Pharmaceutical Industry Association of PR, Inc. 29 th Annual Meeting, November 1 st, 2018 San Juan, Puerto Rico V. Lugo-Flores, Esq VP, Consulting Services J. Niño-Rada, PMP Principal, Health IT L. Pérez-Moreno, MD MPH MHSA President & Managing Principal

2 Driving Innovation in Clinical Practice through Data Analytics ü One of the 1 st steps towards accelerating innovation and demonstrating value of any asset is driving deep local understanding of a patient s journey with disease. Data Information Insights Eureka Clarity of current state Target resource allocation and ROI Address gaps in care Redefine business model Building patient journeys: What you need Improve health gains Multisource/sector data (Is it local, timely and real-world?) Evidence-based clinical consensus guidelines Clinical practice community questionnaires (Does what they say they do match what they do?) Actual interactions with the health care ecosystem (How everything comes together) Financial frameworks in health care management (What are the incentives in-place driving behaviors?) Shoot to the mean/median 2

3 Average Pt. w/ Stage IV, HR+ Breast CA in PR: 66 y/o Avg. Spend/Month (All +55 y/o) Total Exp. (Med + Rx) Rx Exp. $1,000 Tx: $0 Cyclophosphamide (intervals of 2-4 weeks) Doxorubicin (every 3-4 weeks) Paclitaxel (every 3 weeks) $8,000 $6,000 $4,000 $2,000 $0 $733 $737 $796 $295 $288 $396 $1,239 $742 $693 $705 $738 $672 $649 $293 $260 $257 $284 $244 $211 $7,273 $3,477 $2,952 $2,835 $2,599 $490 $574 $541 $478 $146 $170 $128 $117 Jan 17 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec $1,861 $1,557 $1,532 $854 $105 $66 $16 $75 $1,124 $1,743 $2,242 $85 $263 $418 $414 $ Encounters W4 W1 W4 5 th Cycle Disorders of Breast (Feb 7) First encounter Surgeon (Feb 27) Hypertension Breast CA (Dx.: LB CA, Apr 3) Acute Bronchitis First Encounter Oncologist (May 8) Dehydration LOS = 3d Gastroenteritis and Colitis Rx $ 113% Med $ 306% Total $ 239% $105: Azelastine Atorvastatin Tissue exam by pathologist (Feb 27) $66: Atorvastatin Verapamil Er $16: Meloxicam Motion Sickness Relief Clonazepam Tissue exam by pathologist (Apr 3) $75: Doxazosin Prednisolone *W4 (*First Chemo May 23) Potential Abnormality CA Dx. CA Tx $1.124: Diphenhydramine $1,743: Aprepitant W4 W3 W1 *W4 W5 (*Tx. Change Aug 23) 10 Wks. 6 Wks. 13 Wks. CA Tx 14 Wks. $2,242 Aprepitant Filgrastim Change $85 Motion Sickness Relief W3 W5 $263 Verapamil Er Dexamethasone W1 W3 W4 $414 Saline Solutions W3 W4 W5 $414 Saline Solutions $5 Famotidine Clonazepam $291: Other Services $1,173: Echo/Ultrasound $726: Ambulance $7,198: $2,353: $1,209: Ambulance $ 593 : $2,514: Inpatient Serv. $1,598: Surgical Proc $1,143: Other Procedures $1,118: Echo/Ultrasound $849: conjunctiva Hypertension Diabetes breast Noninflam. disorders of genital tract breast Hypertension Sx Emotional State Dig. System Sx Acute LRI DM/CVD CVD Agranulocytosis 2 to chemotherapy Dehydration Other disorders of blood and bloodforming organs Noninfec. Colitis Sx Emotional State Complications of surgical Chemo Cath Dehydration Metabolic disorders thyroid gland DM Acute LRI

4 An Inflection Point for our Health Care Ecosystem ü Understand the current state of clinical management for a specific diagnosis ü Understand the actual costs associated with total patient care for a specific diagnosis ü Build new evidenced-based integrated clinical approaches and proper financial incentives ü Measure clinical gains vs. total cost of providing quality care ü Adjust management strategy Untangle health care s cost and value drivers through analytics to drive efficiency into the system 4

5